search
Back to results

fMRI-neuronavigated rTMS Treatment for Symptoms of Depression Associated With Concussive TBI in the Military Population

Primary Purpose

Traumatic Brain Injury, Concussion, Mild, Depressive Symptoms

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Active: rTMS
Sham: rTMS
Sponsored by
Henry M. Jackson Foundation for the Advancement of Military Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Traumatic Brain Injury focused on measuring Repetitive Transcranial Magnetic Stimulation, Military

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18-64
  2. Current or former US military service member
  3. Eligible for care at DoD facilities
  4. Able to provide written, informed consent in English
  5. History of concussive TBI:

    1. >6 months prior to consent
    2. Documented previously in medical records and/or as confirmed by the TBI Screener
  6. Must meet Criterion A of the DSM-5 criteria for Major Depressive Disorder as determined by a trained assessor
  7. Baseline MADRS >10

Exclusion Criteria:

  1. Elevated risk of seizures:

    1. Prior history of unprovoked seizures other than within 24 hours of concussive TBI
    2. Family history of seizures
    3. History of TBI resulting in penetrating trauma based on the TBI Screener
    4. Presence of intracranial tumor or intraparenchymal hemorrhage based on the structural MRI scan
    5. Heavy alcohol consumption within 48 hours, prior to any treatment session
    6. Receiving tricyclic antidepressants or neuroleptics at doses that lower seizure threshold
  2. Contraindications to awake 3T MRI without contrast:

    1. Ferromagnetic implants or metallic shrapnel
    2. Severe claustrophobia
    3. Unable to lie awake, supine, stationary, with reasonable comfort in the scanner for approximately 45 minutes
    4. Markedly distorted functional brain anatomy such that rsfMRI targeting cannot be performed
  3. History of severe or recent uncontrolled heart disease
  4. Presence of a cardiac pacemaker or intracardiac lines
  5. Implanted neurostimulators and medication pumps
  6. Presence of rapidly progressive illnesses such as late stage cancer, neurodegenerative conditions, major organ failure, etc.
  7. History of Bipolar Disorder, Schizophrenia Spectrum Disorders, or Moderate/Severe Substance Use Disorders, with the exception of nicotine use disorders
  8. Increased risk of suicide as clinically evaluated
  9. Current evidence of substance-induced mood disorder, active psychosis, and/or depression secondary to general medical illness (other than TBI)
  10. Concomitant or previous history of receiving open-label TMS, other neurostimulatory treatment, or electroconvulsive therapy
  11. Pregnancy

    a. Female participants of childbearing potential must agree to use an effective method of birth control during the course of the study, or to remain abstinent from sex, to ensure they do not become pregnant during the course of the study

  12. Unilateral or bilateral upper extremity amputation or other condition precluding motor threshold calibration
  13. Any considerations that, in the opinion of the investigator, may adversely affect patient safety, participation, or the scientific validity of the data being collected (e.g., planned hospitalization halfway through the initial treatment period, limited life expectancy, etc.)

Sites / Locations

  • Walter Reed National Military Medical Center
  • Fort Belvoir Community Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Active: rTMS

Sham: rTMS

Arm Description

Participants will receive 20 bilateral treatment sessions provided over approximately a 5-week period. Daily sessions entail approximately 60 minutes of time.

Sham: Repetitive Transcranial Magnetic Stimulation; Participants will receive sham treatment designed to have similar sound and tactile sensation, without producing active stimulation.

Outcomes

Primary Outcome Measures

Improvement in Depressive Symptoms
Compare change in overall Montgomery-Asberg Depression Rating Scale (MADRS) scores between participants randomized to ICT-rTMS and those randomized to blinded sham stimulation. The overall score ranges from 0 to 60 with a higher overall score indicating more severe depression.

Secondary Outcome Measures

Changes in Cognitive Function
Assess changes in cognitive function and emotion processing as measured by the Automated Neuropsychological Assessment Metric (ANAM).
Changes in TBI-related Symptoms
Assess changes in TBI-related symptoms as reflected by the TBI-QOL.
Changes in PTSD-related Symptoms
Assess changes in PTSD-related symptoms as reflected by the PTSD Checklist for DSM-5 (PCL-5).
Changes in Tinnitus-related Symptoms
To assess changes in tinnitus-related symptoms as reflected by the Mini Tinnitus Questionnaire (Mini TQ-12).
Frequency of Adverse Effects
Compare the frequency and severity of adverse effects between those randomized to ICT-rTMS and those randomized to blinded sham stimulation.
Changes in Psychotherapeutic Changes
Compare the number, dose, and/or type of adjunctive treatments undertaken by those randomized to ICT-rTMS as compared to those randomized to blinded sham stimulation.
Changes in Resting-state fMRI
Assess changes in resting-state functional connectivity using functional magnetic resonance imaging (fMRI).

Full Information

First Posted
December 20, 2017
Last Updated
October 30, 2020
Sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Collaborators
Center for Neuroscience and Regenerative Medicine (CNRM)
search

1. Study Identification

Unique Protocol Identification Number
NCT03523507
Brief Title
fMRI-neuronavigated rTMS Treatment for Symptoms of Depression Associated With Concussive TBI in the Military Population
Official Title
A Randomized, Sham-controlled, Double-blinded Study of Bilateral Prefrontal Individual Connectome-targeted Repetitive Transcranial Magnetic Stimulation to Treat the Symptoms of Depression Associated With Concussive Traumatic Brain Injury.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Terminated
Why Stopped
Study terminated due to COVID-19 restrictions
Study Start Date
July 1, 2019 (Actual)
Primary Completion Date
October 27, 2020 (Actual)
Study Completion Date
October 27, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Collaborators
Center for Neuroscience and Regenerative Medicine (CNRM)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes

5. Study Description

Brief Summary
This study aims to investigate the efficacy and tolerability of fMRI-targeted repetitive transcranial magnetic stimulation (rTMS) in the treatment of depressive symptoms in service members with a history of concussive traumatic brain injury (TBI). Up to ninety participants will be randomized to active or sham treatment. Participants randomized into the active group will receive 20 sessions of left-sided dorsolateral prefrontal cortex (DLFPC) high-frequency rTMS, followed by right-sided DLFPC low-frequency rTMS. The DLPFC treatment area will be identified by using individual subject-level resting state network estimation (Hacker et al., 2013). Participants randomized into the sham treatment group will receive 20 sham treatments designed to have similar sound and tactile sensation, without producing active treatment. Participants will also be asked to complete regular follow-up evaluations for up to a total of six follow-up sessions. Those who do not respond to the treatment will have the option to receive active treatment through this study regardless of group assignment to active or sham.
Detailed Description
This study aims to investigate the efficacy and tolerability of individual connectome-targeted repetitive transcranial magnetic stimulation (ICT-rTMS) treatment to enhance the rehabilitation of service members with symptoms of depression and history of concussive traumatic brain injury (TBI). This will be a multi-site, double-blinded, sham-controlled, prospective, randomized interventional trial. Up to ninety participants will be block randomized to active (ICT-rTMS) or sham treatment. Participants will receive 20 sessions of ICT-rTMS over approximately 5 weeks. Resting-state functional magnetic resonance imaging (rsfMRI) and structural MRI will be obtained at baseline to allow for the calculation of connectome-targeted treatment coordinates and ensure the absence of structural abnormalities. The rsfMRI scan at baseline will also be used to establish the baseline for the secondary imaging outcome measures. Treatment sessions will consist of high-frequency left dorsolateral prefrontal cortex (DLPFC) stimulation for 4,000 pulses followed by low-frequency right DLPFC stimulation for 1,000 pulses for a total stimulation time of approximately one hour per session. This protocol was chosen based on a recent meta-analysis (Brunoni et al., 2017) indicating that amongst the various treatment protocols, priming the low frequency right hemisphere stimulation with a high frequency left hemisphere stimulation led to the greatest efficacy for treatment of Major Depressive Episodes. Additionally, the overwhelming majority of the literature in TMS for depression targets the stimulation to DLPFC and the FDA has approved repetitive transcranial magnetic stimulation (rTMS) to DLPFC for the treatment of medication-resistant major depressive disorder (MDD). The primary outcome will be change in depression severity from baseline to post-treatment. The primary analysis will be a comparison between the ICT-rTMS and sham groups. Secondary outcome measures utilized will include cognitive, quality of life, and emotional regulation measures, as well as imaging changes. Additional analyses will include durability of effects during the 6 months following treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Traumatic Brain Injury, Concussion, Mild, Depressive Symptoms
Keywords
Repetitive Transcranial Magnetic Stimulation, Military

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Active: rTMS
Arm Type
Experimental
Arm Description
Participants will receive 20 bilateral treatment sessions provided over approximately a 5-week period. Daily sessions entail approximately 60 minutes of time.
Arm Title
Sham: rTMS
Arm Type
Sham Comparator
Arm Description
Sham: Repetitive Transcranial Magnetic Stimulation; Participants will receive sham treatment designed to have similar sound and tactile sensation, without producing active stimulation.
Intervention Type
Device
Intervention Name(s)
Active: rTMS
Intervention Description
Daily sessions will consist of 3000 left-sided excitatory pulses at 10 Hz (with 4-second trains and 26-second inter-train interval) followed by 1000 right-sided inhibitory pulses at 1 Hz (in a single train). The DLPFC treatment target will be determined using individualized resting-state network mapping.
Intervention Type
Device
Intervention Name(s)
Sham: rTMS
Intervention Description
Daily sessions will consist of the same total number of sham pulses, designed to have similar sound and tactile sensation, without producing active stimulation.
Primary Outcome Measure Information:
Title
Improvement in Depressive Symptoms
Description
Compare change in overall Montgomery-Asberg Depression Rating Scale (MADRS) scores between participants randomized to ICT-rTMS and those randomized to blinded sham stimulation. The overall score ranges from 0 to 60 with a higher overall score indicating more severe depression.
Time Frame
Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Secondary Outcome Measure Information:
Title
Changes in Cognitive Function
Description
Assess changes in cognitive function and emotion processing as measured by the Automated Neuropsychological Assessment Metric (ANAM).
Time Frame
Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Title
Changes in TBI-related Symptoms
Description
Assess changes in TBI-related symptoms as reflected by the TBI-QOL.
Time Frame
Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Title
Changes in PTSD-related Symptoms
Description
Assess changes in PTSD-related symptoms as reflected by the PTSD Checklist for DSM-5 (PCL-5).
Time Frame
Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Title
Changes in Tinnitus-related Symptoms
Description
To assess changes in tinnitus-related symptoms as reflected by the Mini Tinnitus Questionnaire (Mini TQ-12).
Time Frame
Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Title
Frequency of Adverse Effects
Description
Compare the frequency and severity of adverse effects between those randomized to ICT-rTMS and those randomized to blinded sham stimulation.
Time Frame
Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Title
Changes in Psychotherapeutic Changes
Description
Compare the number, dose, and/or type of adjunctive treatments undertaken by those randomized to ICT-rTMS as compared to those randomized to blinded sham stimulation.
Time Frame
Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Title
Changes in Resting-state fMRI
Description
Assess changes in resting-state functional connectivity using functional magnetic resonance imaging (fMRI).
Time Frame
Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-64 Current or former US military service member Eligible for care at DoD facilities Able to provide written, informed consent in English History of concussive TBI: >6 months prior to consent Documented previously in medical records and/or as confirmed by the TBI Screener Must meet Criterion A of the DSM-5 criteria for Major Depressive Disorder as determined by a trained assessor Baseline MADRS >10 Exclusion Criteria: Elevated risk of seizures: Prior history of unprovoked seizures other than within 24 hours of concussive TBI Family history of seizures History of TBI resulting in penetrating trauma based on the TBI Screener Presence of intracranial tumor or intraparenchymal hemorrhage based on the structural MRI scan Heavy alcohol consumption within 48 hours, prior to any treatment session Receiving tricyclic antidepressants or neuroleptics at doses that lower seizure threshold Contraindications to awake 3T MRI without contrast: Ferromagnetic implants or metallic shrapnel Severe claustrophobia Unable to lie awake, supine, stationary, with reasonable comfort in the scanner for approximately 45 minutes Markedly distorted functional brain anatomy such that rsfMRI targeting cannot be performed History of severe or recent uncontrolled heart disease Presence of a cardiac pacemaker or intracardiac lines Implanted neurostimulators and medication pumps Presence of rapidly progressive illnesses such as late stage cancer, neurodegenerative conditions, major organ failure, etc. History of Bipolar Disorder, Schizophrenia Spectrum Disorders, or Moderate/Severe Substance Use Disorders, with the exception of nicotine use disorders Increased risk of suicide as clinically evaluated Current evidence of substance-induced mood disorder, active psychosis, and/or depression secondary to general medical illness (other than TBI) Concomitant or previous history of receiving open-label TMS, other neurostimulatory treatment, or electroconvulsive therapy Pregnancy a. Female participants of childbearing potential must agree to use an effective method of birth control during the course of the study, or to remain abstinent from sex, to ensure they do not become pregnant during the course of the study Unilateral or bilateral upper extremity amputation or other condition precluding motor threshold calibration Any considerations that, in the opinion of the investigator, may adversely affect patient safety, participation, or the scientific validity of the data being collected (e.g., planned hospitalization halfway through the initial treatment period, limited life expectancy, etc.)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David L Brody, MD, PhD
Organizational Affiliation
Center for Neuroscience and Regenerative Medicine (CNRM)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Walter Reed National Military Medical Center
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20889
Country
United States
Facility Name
Fort Belvoir Community Hospital
City
Fort Belvoir
State/Province
Virginia
ZIP/Postal Code
22060
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Coded data will be deposited into the following repositories: the Center for Neuroscience and Regenerative Medicine (CNRM) Data Repository and the Federal Interagency Traumatic Brain Injury Research (FITBIR) Database.
IPD Sharing Time Frame
Following project completion, a summary of the results will be provided to the site.
IPD Sharing Access Criteria
Access to the data located in the CNRM Repository and FITBIR database will be provided by the respective entities.
Citations:
PubMed Identifier
23735260
Citation
Hacker CD, Laumann TO, Szrama NP, Baldassarre A, Snyder AZ, Leuthardt EC, Corbetta M. Resting state network estimation in individual subjects. Neuroimage. 2013 Nov 15;82:616-633. doi: 10.1016/j.neuroimage.2013.05.108. Epub 2013 Jun 2.
Results Reference
background
PubMed Identifier
28030740
Citation
Brunoni AR, Chaimani A, Moffa AH, Razza LB, Gattaz WF, Daskalakis ZJ, Carvalho AF. Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes: A Systematic Review With Network Meta-analysis. JAMA Psychiatry. 2017 Feb 1;74(2):143-152. doi: 10.1001/jamapsychiatry.2016.3644. Erratum In: JAMA Psychiatry. 2017 Apr 1;74(4):424.
Results Reference
background

Learn more about this trial

fMRI-neuronavigated rTMS Treatment for Symptoms of Depression Associated With Concussive TBI in the Military Population

We'll reach out to this number within 24 hrs